Epigenetic alterations of the Wnt signaling pathway in cancer: A mini review

Bosnian Journal of Basic Medical Sciences

Volumn 14, Issue 4, 2014, Pages 191-194

  Serman, Ljiljana ^a   Martic, Tamara Nikuseva ^a   Serman, Alan ^b   Vranic, Semir ^c  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Croatian Academy of Medical Sciences   (Croatia)

^c UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

Cancer; Epigenetics; Wnt signaling pathway

Indexed keywords

CELL DIFFERENTIATION; CELL MOTION; CELL PROLIFERATION; DNA METHYLATION; FEMALE; GENETIC EPIGENESIS; GENETICS; HUMAN; MALE; METABOLISM; NEOPLASM; PATHOLOGY; WNT SIGNALING PATHWAY;

CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; MALE; NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84916887899     PISSN: 15128601     EISSN: 18404812     Source Type: Journal    
DOI: 10.17305/bjbms.2014.4.205     Document Type: Article

References (37)

1. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Epigenetics 2007;128:635-638.
2. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27. http://dx.doi.org/10.1016/j. cell.2012.06.013.
3. Serman A, Vlahovic M, Serman L, Bulic-Jakus F. DNA methylation as regulatory mechanism for gene expression in mammals. Coll Antropol 2006;30:665-671.
4. Baylin SB, Jones PA. A decade of exploring the cancer epigenome- biological and translational implications. Nat Rev Cancer 2011;11:726-734. http://dx.doi.org/10.1038/nrc3130.
5. Brookes E, Shi Y. Diverse epigenetic mechanisms of human disease. Annu Rev Genet 2014; doi:10.1146/annurev-genet-120213-092518. http://dx.doi.org/10.1146/annurev-genet-120213-092518.
6. Hattori N, Ushijima T. Compentium of aberrant DNA methylation and histone modiflcation in cancer. Biochem Biophys Res Commun 2014; doi: 10.1016/j.bbrc.2014.08.140. http://dx.doi.org/10.1016/j. bbrc.2014.08.140.
7. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-1080. http://dx.doi.org/10.1126/science.1063127.
8. Miceli M, Bontempo P, Nebbioso A, Altucci L. Natural compounds in epigenetics: A current view. Food Chem Toxicol 2014;73C:71-83. http://dx.doi.org/10.1016/j.fct.2014.08.005.
9. Geutjes EJ, Bajpe PK, Bernards RB. Targeting the epigenome for treatment of cancer. Oncogene 2012;2012:3827-3844. http://dx.doi. org/10.1038/onc.2011.552.
10. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008; 54:414-423. http://dx.doi.org/10.1373/ clinchem.2007.095992.
11. Millar DS, Ow KK, Paul CL, Russell PJ, Molloy PL, Clark SJ. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 1999;18:1313-1324. http://dx.doi. org/10.1038/sj.onc.1202415.
12. Jimenez RE, Fischer AH, Petros JA, Amin MB. Glutathione S-transferase pi gene methylation: the search for a molecular marker of prostatic adenocarcinoma. Adv Anat Pathol 2000;7:382-389. http://dx.doi.org/10.1097/00125480-200007060-00005.
13. Surana R, Sikka S, Cai W, Shin EM, Warrier SR, Tan HJ, et al. Secreted frizzled related proteins: Implications in cancers. Biochim Biophys Acta 2014;1845:53-65.
14. Widelitz R. Wnt signaling through canonical and non-canonical pathways: recent progress. Growth Factors 2005;23:111-116. http:// dx.doi.org/10.1080/08977190500125746.
15. Staal FJ, Clevers HC. WNT signalling and haematopoiesis: a WNTWNT situation. Nat Rev Immunol 2005;5:21-30. http://dx.doi. org/10.1038/nri1529.
16. Bonci D, Coppola V, Musumeci M, Addario A, Giuff rida R, Memeo L, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008;14:1271-1277. http://dx.doi.org/10.1038/nm.1880.
17. Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, et al. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res 2003;63:4547-4551.
18. Terasaki H, Saitoh T, Shiokawa K, Katoh M. Frizzled-10, upregulated in primary colorectal cancer, is a positive regulator of the WNT-beta-catenin-TCF signaling pathway. Int J Mol Med 2002;9:107-112.
19. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005;19:877-890. http://dx. doi.org/10.1101/gad.1295405.
20. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
21. Batra S, Shi Y, Kuchenbecker KM, He B, Reguart N, Mikami I, et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun 2006; 342:1228-1232. http://dx.doi. org/10.1016/j.bbrc.2006.02.084.
22. Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C. CpG island methylation and expression of the secreted frizzled-related protein gene familyin chronic lymphocytic leukemia. Cancer Res 2006;66:653-658. http://dx.doi.org/10.1158/0008-5472. CAN-05-3712.
23. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-422. http://dx.doi.org/10.1038/ng1330.
24. Katoh M. Expression and regulation of WNT1 in human cancer: upregulation of WNT1 by beta-estradiol in MCF-7 cells. Int J Oncol 2003;22:209-212.
25. Bonci D, Coppola V, Musumeci M, Addario A, Giuff rida R, Memeo L, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008;14:1271-1277. http://dx.doi.org/10.1038/nm.1880.
26. Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H, et al. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothe¬lial growth factor-an expression in non-small-cell lung cancer. J Clin Oncol 2005;23:8765-8773. http://dx.doi.org/10.1200/JCO.2005.02.2871.
27. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, et al. WNT5A exhibits tumor-sup-pressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 2008;14:55-61. http://dx.doi. org/10.1158/1078-0432.CCR-07-1644.
28. Ying J, Li H, Chen YW, Srivastava G, Gao Z, Tao Q. WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood 2007;110:4130-4132. http://dx.doi.org/10.1182/blood-2007-06-094870.
29. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003;63:3735-3742.
30. Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, et al. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res 2006;66:5077-5084. http://dx.doi.org/10.1158/0008- 5472.CAN-05-2629.
31. Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006;25:3479-3488. http://dx.doi.org/10.1038/sj.onc.1209386.
32. Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knuchel R, et al. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-speciflc epigenetic marker in human breast cancer. Mol Cancer 2008;7:83. http://dx.doi. org/10.1186/1476-4598-7-83.
33. Chim CS, Chan WW, Pang A, Kwong YL. Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic leukemia: an independent poor prognostic factor. Leukemia 2006;20:907-909. http://dx.doi.org/10.1038/sj.leu.2404176.
34. Yu J, Tao Q, Cheng YY, Lee KY, Ng SS, Cheung KF, et al. Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 2009;115:49-60. http://dx.doi.org/10.1002/cncr.23989.
35. Prasad CP, Mirza S, Sharma G, Prashad R, DattaGupta S, Rath G, et al. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sci 2008;83:318-325. http://dx.doi. org/10.1016/j.lfs.2008.06.019.
36. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004;6:151-158. http://dx.doi.org/10.1016/j. ccr.2004.06.023.
37. Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007;9:1-24. http://dx.doi.org/10.1017/S1462399407000312.